| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
|
N Engl J Med
|
2005
|
28.25
|
|
2
|
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
|
N Engl J Med
|
2005
|
12.99
|
|
3
|
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
|
Lancet
|
2007
|
9.24
|
|
4
|
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
|
J Clin Oncol
|
2007
|
7.45
|
|
5
|
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
|
Lancet
|
2012
|
7.31
|
|
6
|
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
|
Lancet Oncol
|
2013
|
6.79
|
|
7
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
6.76
|
|
8
|
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
|
J Natl Cancer Inst
|
2012
|
5.27
|
|
9
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
5.18
|
|
10
|
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
|
Lancet Oncol
|
2011
|
4.67
|
|
11
|
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
|
N Engl J Med
|
2009
|
4.16
|
|
12
|
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
|
J Clin Oncol
|
2011
|
3.53
|
|
13
|
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
|
J Clin Oncol
|
2006
|
3.52
|
|
14
|
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
|
J Clin Oncol
|
2007
|
3.38
|
|
15
|
Breast cancer.
|
Lancet
|
2005
|
3.27
|
|
16
|
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
|
J Natl Cancer Inst
|
2008
|
3.16
|
|
17
|
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
|
J Natl Cancer Inst
|
2003
|
3.16
|
|
18
|
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
|
J Clin Oncol
|
2006
|
3.15
|
|
19
|
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
|
J Clin Oncol
|
2008
|
3.14
|
|
20
|
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
|
J Clin Oncol
|
2009
|
2.98
|
|
21
|
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
|
J Clin Oncol
|
2008
|
2.93
|
|
22
|
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.
|
J Clin Oncol
|
2005
|
2.58
|
|
23
|
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
|
Lancet Oncol
|
2011
|
2.51
|
|
24
|
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
|
Clin Cancer Res
|
2004
|
2.46
|
|
25
|
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
|
Lancet Oncol
|
2007
|
2.44
|
|
26
|
Rethinking TNM: breast cancer TNM classification for treatment decision-making and research.
|
Breast
|
2006
|
2.36
|
|
27
|
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
|
J Natl Cancer Inst
|
2003
|
2.25
|
|
28
|
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.
|
J Clin Oncol
|
2008
|
2.14
|
|
29
|
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
|
J Clin Oncol
|
2008
|
2.10
|
|
30
|
Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.
|
J Clin Oncol
|
2012
|
2.08
|
|
31
|
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.
|
Lancet
|
2005
|
2.04
|
|
32
|
International Web-based consultation on priorities for translational breast cancer research.
|
Breast Cancer Res
|
2007
|
2.02
|
|
33
|
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
|
Breast Cancer Res Treat
|
2010
|
1.97
|
|
34
|
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
|
J Natl Cancer Inst
|
2008
|
1.95
|
|
35
|
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
|
Breast
|
2013
|
1.94
|
|
36
|
Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.
|
Breast Cancer Res Treat
|
2009
|
1.93
|
|
37
|
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
|
J Natl Cancer Inst
|
2006
|
1.89
|
|
38
|
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?
|
Cancer
|
2003
|
1.88
|
|
39
|
Autologous fat transplantation in patients with breast cancer: "silencing" or "fueling" cancer recurrence?
|
Breast
|
2011
|
1.80
|
|
40
|
Adjuvant endocrine therapy for premenopausal women with early breast cancer.
|
J Clin Oncol
|
2005
|
1.71
|
|
41
|
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.
|
Blood
|
2006
|
1.69
|
|
42
|
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
|
Cancer Chemother Pharmacol
|
2007
|
1.66
|
|
43
|
Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
|
Breast Cancer Res Treat
|
2008
|
1.62
|
|
44
|
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
|
J Clin Oncol
|
2005
|
1.61
|
|
45
|
Breast cancer in the elderly.
|
J Clin Oncol
|
2007
|
1.60
|
|
46
|
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
|
J Clin Oncol
|
2010
|
1.51
|
|
47
|
Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"?
|
Breast
|
2013
|
1.51
|
|
48
|
Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients.
|
Cancer
|
2004
|
1.48
|
|
49
|
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.48
|
|
50
|
Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement.
|
J Clin Oncol
|
2005
|
1.47
|
|
51
|
Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.46
|
|
52
|
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
|
J Clin Oncol
|
2013
|
1.45
|
|
53
|
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
|
J Clin Oncol
|
2002
|
1.44
|
|
54
|
Breast cancer classification: time for a change.
|
J Clin Oncol
|
2009
|
1.43
|
|
55
|
Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter.
|
Support Care Cancer
|
2007
|
1.42
|
|
56
|
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
|
Breast
|
2012
|
1.39
|
|
57
|
Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.
|
J Clin Oncol
|
2003
|
1.38
|
|
58
|
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
|
J Clin Oncol
|
2008
|
1.34
|
|
59
|
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
|
Breast Cancer Res Treat
|
2008
|
1.31
|
|
60
|
Breast phyllodes tumor: a review of literature and a single center retrospective series analysis.
|
Crit Rev Oncol Hematol
|
2013
|
1.30
|
|
61
|
Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
|
Eur J Cancer
|
2007
|
1.28
|
|
62
|
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.
|
Ann Oncol
|
2004
|
1.28
|
|
63
|
Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy.
|
Breast Cancer Res Treat
|
2008
|
1.24
|
|
64
|
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
|
BMC Cancer
|
2006
|
1.24
|
|
65
|
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.
|
Breast Cancer Res
|
2014
|
1.20
|
|
66
|
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.
|
Breast Cancer Res Treat
|
2009
|
1.20
|
|
67
|
Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice.
|
Oncology
|
2008
|
1.17
|
|
68
|
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.
|
Breast Cancer Res
|
2005
|
1.17
|
|
69
|
Keeping faith with trial volunteers.
|
Nature
|
2007
|
1.13
|
|
70
|
Invasive lobular breast cancer: subtypes and outcome.
|
Breast Cancer Res Treat
|
2012
|
1.11
|
|
71
|
Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution.
|
Cancer
|
2004
|
1.11
|
|
72
|
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
|
J Clin Oncol
|
2006
|
1.10
|
|
73
|
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.
|
J Clin Oncol
|
2007
|
1.10
|
|
74
|
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
|
Anticancer Drugs
|
2006
|
1.09
|
|
75
|
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
|
Breast
|
2010
|
1.09
|
|
76
|
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.
|
Clin Cancer Res
|
2009
|
1.07
|
|
77
|
Pregnancy after breast cancer: if you wish, ma'am.
|
Breast Cancer Res Treat
|
2011
|
1.07
|
|
78
|
Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.
|
Clin Breast Cancer
|
2012
|
1.05
|
|
79
|
Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.
|
Clin Breast Cancer
|
2010
|
1.05
|
|
80
|
Cardiac toxicity from systemic cancer therapy: a comprehensive review.
|
Prog Cardiovasc Dis
|
2010
|
1.04
|
|
81
|
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
|
J Clin Oncol
|
2007
|
1.04
|
|
82
|
Is adjuvant chemotherapy useful for women with luminal a breast cancer?
|
J Clin Oncol
|
2012
|
1.03
|
|
83
|
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
|
J Clin Oncol
|
2012
|
1.03
|
|
84
|
Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.
|
Breast Cancer Res Treat
|
2013
|
1.02
|
|
85
|
A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer.
|
Eur J Cancer
|
2010
|
1.00
|
|
86
|
Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells.
|
Cancer Res
|
2004
|
1.00
|
|
87
|
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
|
Breast Cancer Res Treat
|
2008
|
1.00
|
|
88
|
The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
|
J Natl Cancer Inst Monogr
|
2011
|
1.00
|
|
89
|
Molecular pathways: human leukocyte antigen G (HLA-G).
|
Clin Cancer Res
|
2013
|
1.00
|
|
90
|
Vaccine immunotherapy in breast cancer treatment: promising, but still early.
|
Expert Rev Anticancer Ther
|
2007
|
0.99
|
|
91
|
Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
|
Clin Breast Cancer
|
2012
|
0.98
|
|
92
|
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.
|
Breast Cancer Res
|
2012
|
0.98
|
|
93
|
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression.
|
Cancer Chemother Pharmacol
|
2007
|
0.98
|
|
94
|
Clinical trial update: International Breast Cancer Study Group.
|
Breast Cancer Res
|
2005
|
0.97
|
|
95
|
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
|
Breast Cancer Res Treat
|
2010
|
0.97
|
|
96
|
Results of chest wall resection for recurrent or locally advanced breast malignancies.
|
Breast
|
2007
|
0.97
|
|
97
|
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients.
|
Cancer
|
2011
|
0.96
|
|
98
|
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials.
|
Cancer Treat Rev
|
2012
|
0.96
|
|
99
|
HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
|
Eur J Cancer
|
2007
|
0.95
|
|
100
|
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
|
Clin Breast Cancer
|
2012
|
0.94
|
|
101
|
Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer.
|
Breast Cancer Res Treat
|
2005
|
0.94
|
|
102
|
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
|
Breast
|
2013
|
0.94
|
|
103
|
The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study.
|
Acta Oncol
|
2011
|
0.93
|
|
104
|
Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.
|
Clin Breast Cancer
|
2010
|
0.93
|
|
105
|
Breast cancer and pregnancy: how safe is trastuzumab?
|
Nat Rev Clin Oncol
|
2009
|
0.91
|
|
106
|
Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives.
|
Breast Cancer Res
|
2014
|
0.91
|
|
107
|
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
|
Cancer
|
2003
|
0.91
|
|
108
|
Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer.
|
Acta Oncol
|
2013
|
0.91
|
|
109
|
Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.
|
Breast
|
2009
|
0.91
|
|
110
|
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
|
Breast Cancer Res Treat
|
2004
|
0.91
|
|
111
|
Prediction of cancer outcome with microarrays.
|
Lancet
|
2005
|
0.91
|
|
112
|
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.
|
Breast
|
2013
|
0.89
|
|
113
|
Conservative surgery in patients with multifocal/multicentric breast cancer.
|
Breast Cancer Res Treat
|
2008
|
0.89
|
|
114
|
Sentinel lymph node biopsy in pregnant patients with breast cancer.
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.89
|
|
115
|
Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
|
J Clin Oncol
|
2006
|
0.87
|
|
116
|
The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy.
|
Breast Cancer Res Treat
|
2010
|
0.87
|
|
117
|
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
|
J Clin Oncol
|
2005
|
0.87
|
|
118
|
Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast?
|
J Clin Oncol
|
2010
|
0.86
|
|
119
|
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
|
Ann Oncol
|
2007
|
0.86
|
|
120
|
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
|
Anticancer Drugs
|
2009
|
0.86
|
|
121
|
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
|
Cancer
|
2006
|
0.85
|
|
122
|
Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.
|
Eur J Cancer
|
2007
|
0.85
|
|
123
|
Immune approaches to the treatment of breast cancer, around the corner?
|
Breast Cancer Res
|
2014
|
0.85
|
|
124
|
Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features.
|
Clin Breast Cancer
|
2004
|
0.85
|
|
125
|
Weekly epirubicin in the treatment of gestational breast cancer (GBC).
|
Breast Cancer Res Treat
|
2008
|
0.85
|
|
126
|
Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
|
Breast
|
2008
|
0.85
|
|
127
|
Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation.
|
Breast Cancer Res Treat
|
2011
|
0.85
|
|
128
|
Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer.
|
Clin Breast Cancer
|
2006
|
0.85
|
|
129
|
Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat.
|
Eur J Haematol
|
2004
|
0.84
|
|
130
|
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.
|
Eur J Cancer
|
2008
|
0.84
|
|
131
|
"Burned out" phenomenon of the testis in retroperitoneal seminoma.
|
Acta Oncol
|
2006
|
0.84
|
|
132
|
Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series.
|
Breast Cancer Res Treat
|
2008
|
0.83
|
|
133
|
Biopsy of liver metastasis for women with breast cancer: impact on survival.
|
Breast
|
2011
|
0.83
|
|
134
|
Drug-induced immune thrombocytopenia.
|
N Engl J Med
|
2007
|
0.83
|
|
135
|
Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.
|
Anticancer Res
|
2009
|
0.82
|
|
136
|
Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.82
|
|
137
|
Focusing on physical function limitations in elderly women surviving cancer: any opportunity for improvement?
|
Nat Clin Pract Oncol
|
2006
|
0.82
|
|
138
|
"Waiting and the waiting room: how do you experience them?" emotional implications and suggestions from patients with cancer.
|
J Cancer Educ
|
2010
|
0.82
|
|
139
|
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.
|
Breast Cancer Res Treat
|
2009
|
0.81
|
|
140
|
Erlotinib-induced breast cancer regression.
|
Ann Pharmacother
|
2006
|
0.81
|
|
141
|
Dendritic cell-based vaccines: clinical applications in breast cancer.
|
Immunotherapy
|
2014
|
0.81
|
|
142
|
Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis.
|
Support Cancer Ther
|
2006
|
0.81
|
|
143
|
Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
|
Clin Breast Cancer
|
2012
|
0.81
|
|
144
|
Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy.
|
Cancer Treat Rev
|
2010
|
0.80
|
|
145
|
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer.
|
Breast
|
2011
|
0.80
|
|
146
|
Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?
|
Anticancer Drugs
|
2012
|
0.80
|
|
147
|
Immunizing against breast cancer: a new swing for an old sword.
|
Breast
|
2009
|
0.80
|
|
148
|
Chemotherapy during pregnancy: what is really safe?
|
Lancet Oncol
|
2004
|
0.80
|
|
149
|
Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome.
|
J Surg Oncol
|
2006
|
0.80
|
|
150
|
Immunology and breast cancer: therapeutic cancer vaccines.
|
Breast
|
2007
|
0.80
|
|
151
|
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
|
Breast Cancer Res Treat
|
2015
|
0.79
|
|
152
|
Locoregional recurrence in patients with HER2 positive breast cancer.
|
Breast
|
2013
|
0.79
|
|
153
|
Intrathecal chemotherapy in carcinomatous meningitis from breast cancer.
|
Anticancer Res
|
2003
|
0.78
|
|
154
|
Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group.
|
Support Care Cancer
|
2007
|
0.78
|
|
155
|
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
|
Breast Cancer Res Treat
|
2004
|
0.78
|
|
156
|
Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
|
Breast J
|
2008
|
0.77
|
|
157
|
Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases.
|
Breast Cancer Res Treat
|
2013
|
0.77
|
|
158
|
New criteria for selecting elderly patients for breast cancer adjuvant treatment studies.
|
Oncologist
|
2007
|
0.77
|
|
159
|
Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors.
|
Breast
|
2008
|
0.77
|
|
160
|
Successful treatment with low-dose oral chemotherapy in a patient with metastatic hepatocellular carcinoma.
|
Acta Oncol
|
2007
|
0.77
|
|
161
|
Breast cancer.
|
Discov Med
|
2005
|
0.76
|
|
162
|
Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
|
J Natl Cancer Inst
|
2007
|
0.76
|
|
163
|
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
|
Breast
|
2010
|
0.76
|
|
164
|
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.
|
Anticancer Drugs
|
2006
|
0.76
|
|
165
|
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
|
Breast Cancer Res Treat
|
2011
|
0.76
|
|
166
|
Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.
|
Breast J
|
2012
|
0.76
|
|
167
|
Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
|
Breast
|
2013
|
0.76
|
|
168
|
Breast cancer in young women: climbing for progress in care and knowledge.
|
Womens Health (Lond Engl)
|
2006
|
0.75
|
|
169
|
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
|
Breast Cancer Res Treat
|
2014
|
0.75
|
|
170
|
To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer.
|
Nat Clin Pract Oncol
|
2007
|
0.75
|
|
171
|
Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
|
Breast Cancer Res Treat
|
2007
|
0.75
|
|
172
|
Life with consequences of breast cancer: pregnancy during and after endocrine therapies.
|
Breast
|
2004
|
0.75
|
|
173
|
The 6th Milan Breast Cancer Conference, Milan, Italy, 16-18 June 2004.
|
Breast Cancer Res
|
2004
|
0.75
|
|
174
|
Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song.
|
J Clin Oncol
|
2005
|
0.75
|
|
175
|
Adjuvant chemotherapy in breast cancer: back to the future.
|
Onkologie
|
2003
|
0.75
|
|
176
|
Hormonal treatment duration in elderly patients: an open question.
|
J Clin Oncol
|
2004
|
0.75
|
|
177
|
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.
|
Breast
|
2012
|
0.75
|
|
178
|
Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer.
|
Breast
|
2009
|
0.75
|
|
179
|
Comparing aromatase inhibitors in the absence of clinical trial results can be misleading.
|
J Surg Oncol
|
2007
|
0.75
|
|
180
|
Metronomic chemotherapy in elderly patients: do risks exceed benefits in some patients?
|
Tumori
|
2009
|
0.75
|
|
181
|
Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.
|
Nat Rev Clin Oncol
|
2012
|
0.75
|
|
182
|
Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer.
|
Breast
|
2010
|
0.75
|
|
183
|
Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma.
|
Hepatogastroenterology
|
2007
|
0.75
|
|
184
|
Do early breast cancer patients with only sentinel lymph node biopsy experience lower psychological morbidity over time?
|
Breast J
|
2012
|
0.75
|
|
185
|
Targeting the subtypes of breast cancer: rethinking investigational drugs.
|
Expert Opin Investig Drugs
|
2012
|
0.75
|
|
186
|
Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer.
|
Breast
|
2006
|
0.75
|
|
187
|
An interview with Dr. Aron Goldhirsch.
|
Eur J Cancer
|
2002
|
0.75
|
|
188
|
QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review.
|
Target Oncol
|
2014
|
0.75
|
|
189
|
Mediastinal lymphoadenopathy in a patient with breast cancer.
|
Lancet Oncol
|
2002
|
0.75
|
|
190
|
Exemestane seems to stimulate tumour growth in men with prostate carcinoma.
|
Eur J Cancer
|
2003
|
0.75
|
|
191
|
Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series.
|
Int J Clin Oncol
|
2014
|
0.75
|
|
192
|
Adjuvant systemic therapies for patients with breast cancer: endocrine responsiveness and effects of chemotherapy.
|
Curr Probl Cancer
|
2003
|
0.75
|
|
193
|
Overhauling the breast cancer overview: are subsets subversive?
|
Lancet Oncol
|
2002
|
0.75
|
|
194
|
Innovation in care and research: meeting highlights from the seventh Milan Breast Cancer Conference (Milan, 15-17 June, 2005).
|
Breast
|
2006
|
0.75
|
|
195
|
No link between breast cancer and meningioma: results from a large monoinstitutional retrospective analysis.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.75
|